Leerink Partnrs Weighs in on Kyverna Therapeutics, Inc.’s FY2024 Earnings (NASDAQ:KYTX)

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Stock analysts at Leerink Partnrs decreased their FY2024 EPS estimates for Kyverna Therapeutics in a report released on Monday, August 12th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings per share of ($3.54) for the year, down from their previous forecast of ($3.51). The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.34) per share. Leerink Partnrs also issued estimates for Kyverna Therapeutics’ Q4 2024 earnings at ($1.03) EPS and FY2027 earnings at ($5.78) EPS.

Kyverna Therapeutics (NASDAQ:KYTX) last announced its earnings results on Monday, August 12th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.70) by $0.03.

KYTX has been the subject of several other research reports. HC Wainwright decreased their target price on Kyverna Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research report on Thursday. JPMorgan Chase & Co. decreased their price objective on shares of Kyverna Therapeutics from $39.00 to $33.00 and set an “overweight” rating for the company in a report on Wednesday, July 31st. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.40.

Kyverna Therapeutics Trading Down 3.2 %

Shares of NASDAQ:KYTX opened at $6.74 on Thursday. Kyverna Therapeutics has a 1 year low of $6.30 and a 1 year high of $35.06. The firm’s 50-day simple moving average is $8.63.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Federated Hermes Inc. bought a new stake in shares of Kyverna Therapeutics in the 2nd quarter valued at about $120,000. Rhumbline Advisers purchased a new position in shares of Kyverna Therapeutics in the second quarter worth about $150,000. DekaBank Deutsche Girozentrale acquired a new stake in Kyverna Therapeutics during the 1st quarter valued at approximately $181,000. Skandinaviska Enskilda Banken AB publ grew its position in Kyverna Therapeutics by 55.8% during the 2nd quarter. Skandinaviska Enskilda Banken AB publ now owns 26,195 shares of the company’s stock worth $196,000 after purchasing an additional 9,385 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in Kyverna Therapeutics by 32.6% during the second quarter. The Manufacturers Life Insurance Company now owns 37,794 shares of the company’s stock worth $283,000 after acquiring an additional 9,300 shares during the period. Hedge funds and other institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.